Volume 100 in the series of comprises an update and review of relevant information on all agents determined to induce cancer in humans. These Group 1 agents are categorized in 6 (Volumes 100A-F) published in 2012. This paper describes the methodology and stringent criteria used in the creation of a comprehensive database on tumors noted in animals and humans for the carcinogens reviewed in Volume 100, and for additional Group 1 agents that were identified in subsequent through Volume 109. The development of this database involved the systematic collection of relevant data on tumors detected in humans and experimental animals identified by the Working Groups that conducted evaluations reported in the . The database includes all human tumor sites identified by the Working Groups, along with all tumor sites for which there was sufficient evidence in experimental animals. This database provides a basis for assessing the degree of concordance between tumor sites observed in humans and experimental animals for Group 1 agents identified through Volume 109.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10937404.2019.1642601 | DOI Listing |
J Obstet Gynaecol India
December 2024
Department of Surgical Oncology, SMS Medical College and Attached Group of Hospitals, B 31 Prabhu Marg Tilak Nagar, Jaipur, 302004 India.
Background: Vulval cancers account for 0.25% of new cancer cases and 0.2% of new deaths of all sites worldwide making it an uncommon malignancy according to Global cancer Statistics 2020.
View Article and Find Full Text PDFJ Cutan Pathol
January 2025
Department of Pathology and Dermatology, NYU Langone Medical Center, New York, New York, USA.
Background: Digital papillary adenocarcinoma (DPAC) is a rare but aggressive cutaneous malignant sweat gland neoplasm that occurs on acral sites. Despite its clinical significance, the cellular and genetic characteristics of DPAC remain incompletely understood.
Methods: We conducted a comprehensive genomic and transcriptomic analysis of DPAC (n = 14) using targeted next-generation DNA and RNA sequencing, along with gene expression profiling employing the Nanostring Technologies nCounter IO 360 Panel.
Phytother Res
January 2025
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Safe and effective treatments for psoriasis are limited. Anisole is an active ingredient in citrus and basil volatile oils; however, its potential for psoriasis treatment remains unexplored. To investigate the effects and mechanism of anisole transdermal administration as a treatment for psoriasis.
View Article and Find Full Text PDFRecent Adv Drug Deliv Formul
December 2024
Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Pharmaceutics, Gujarat, India.
The development of precise and reliable cancer treatments has been a long-standing goal in oncology. Conventional therapies often affect healthy tissues, leading to significant side effects. To overcome these challenges, researchers are exploring new methodologies that combine advanced drug delivery systems with state-of-the-art imaging technologies to target tumors more effectively.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Cancer Hospital Affiliated to University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
SIRT6, a member of the sirtuin protein family, is recognized as a tumor suppressor. This study investigates the evolutionary history of the SIRT gene family and examines the selective pressures shaping their functional divergence. Insights into the evolution of these genes may enhance our understanding of their roles in disease pathology.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!